Home›Stock Screener›Ajanta Pharma

Ajanta Pharma Share Price Today | Stock Price & Ajanta Pharma Share Screener

AJANTPHARM Pharmaceuticals & Biotechnology
Live Share Price NSE
₹3273.80
▼ -38.70 (-1.17%)
2026-11-18 00:00:00
Live Share Price BSE
₹3271.90
▼ -39.30 (-1.19%)
2026-11-18 00:00:00

As of November 18, 2026, the live Ajanta Pharma share price (NSE: AJANTPHARM) is ₹3,273.80 on NSE and ₹3,271.90 on BSE, down 1.17% from the previous close, with shares trading between ₹3,268.00 and ₹3,340.00 in today's trading session, and a 52-week range of ₹2,485.70–₹3,718.20. Track AJANTPHARM market cap trends to gauge the company's total market size. Use the Ajanta Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Ajanta Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹1,832 and net income of ₹388, with EBITDA of ₹585, an operating margin of 31.0% and a profit margin of 21.2%.

Ajanta Pharma Market Cap ₹41,993.73 Cr.
AJANTPHARM P/E Ratio (TTM) 32.50
Ajanta Pharma P/B Ratio 8.45
EPS (TTM) ₹84.53
Dividend Yield 0.97%
Debt to Equity 0.04
AJANTPHARM 52 Week High ₹3718.20
Ajanta Pharma 52 Week Low ₹2485.70
Operating Margin 31.00%
Profit Margin 21.18%
AJANTPHARM Revenue (TTM) ₹1,832.00
EBITDA ₹585.00
Net Income ₹388.00
Total Assets ₹6,155.00
Total Equity ₹4,527.00

Ajanta Pharma Share Price Chart

Track the current stock price of Ajanta Pharma with an interactive chart. Analyse AJANTPHARM share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Ajanta Pharma stock quote in one place.

The quote of ₹3,273.80 sits between the 52-week low of ₹2,485.70 and the 52-week high of ₹3,718.20, and the latest session moved -1.17% from the previous close.

Ajanta Pharma Company Profile - Fundamental Screener

Screen Ajanta Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AJANTPHARM shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Mannalal B Agrawal listed as chairperson or CEO, and it trades under ISIN INE031B01049.

Business Overview

Ajanta Pharma is an Indian specialty pharmaceutical company focusing on branded generic products. It operates in India, Asia, Africa, and the USA, offering a range of therapeutic products including cardiology, dermatology, ophthalmology, and pain management. The company has seven manufacturing facilities in India and Mauritius, with two approved by the...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Mannalal B Agrawal
ISIN INE031B01049

Ajanta Pharma Balance Sheet Screener

Screen AJANTPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹6,155, up from ₹5,015 in 2025.

Latest statistics put total assets at ₹6,155 and shareholder funds at ₹4,527, with a leverage ratio of 0.04.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 6,155 5,015 4,638 4,679 4,056 3,779 3,319 2,696 2,449 1,848
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 1,867 1,762 1,479 1,496 1,512 1,541 1,472 1,178 1,053 589

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 212 229 175 152 144 135 114 73 61 33
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 4,527 3,790 3,567 3,388 3,264 2,996 2,599 2,245 2,041 1,568
Share Capital 25 25 25 25 17 17 18 18 18 18
Reserves & Surplus 4,502 3,765 3,542 3,363 3,247 2,978 2,581 2,228 2,024 1,550

Ajanta Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Ajanta Pharma income statement and profit fundamentals. Analyze AJANTPHARM quarterly results. Ajanta Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹1,832 and net profit was ₹388, equal to earnings per unit of ₹31.07, at an operating margin of 31%.

In that period expenses were ₹1,247, interest cost ₹2 and tax ₹147. The next period listed, 2026-Jun, shows revenue of ₹1,697 and net profit of ₹334.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 1,832 1,697 1,483 1,400 1,413 1,329 1,189 1,177 1,206 1,171 1,090 1,119 1,050 1,053 919
Expenses 1,247 1,202 1,088 993 1,026 951 873 825 876 815 776 791 738 750 733

Operating Costs and Margins

EBITDA 585 495 395 407 387 378 315 351 331 357 314 328 312 303 186
Operating Profit % 31.00% 26.00% 23.00% 28.00% 24.00% 27.00% 25.00% 28.00% 26.00% 29.00% 26.00% 28.00% 28.00% 27.00% 17.00%
Depreciation 48 45 45 44 43 41 40 36 34 34 34 34 34 33 33
Interest 2 3 2 5 3 5 6 8 6 1 2 3 2 1 1

Profit and Earnings

Profit Before Tax 535 447 347 359 341 331 269 307 290 322 278 291 276 269 152
Tax 147 113 80 85 81 76 44 75 74 76 75 81 81 61 30
Net Profit 388 334 267 274 260 255 225 233 217 246 203 210 195 208 122
EPS 31.07 26.75 21.35 21.91 20.83 20.44 18.00 18.60 17.27 19.54 16.10 16.68 15.51 16.53 9.54

Ajanta Pharma Cash Flow Screener - Liquidity Fundamentals

Screen AJANTPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹529, and net cash flow was an outflow of ₹68.

Over the same period, investing activities used ₹429 and financing activities used ₹168.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 529 1,157 785 792 562 576 457 375 281 609
Investing Activities -429 -377 65 -560 -74 -282 -224 -223 -256 -383

Financing and Net Cash

Financing Activities -168 -733 -1,051 -108 -460 -318 -129 -148 0 -202
Net Cash Flow -68 47 -201 124 28 -24 104 4 25 24

Ajanta Pharma Shareholding Pattern Screener

See Ajanta Pharma shareholding pattern with promoter, FII, and DII holdings. Check Ajanta Pharma promoter holding and ownership changes for AJANTPHARM on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 63.47%, foreign institutions 7.63%, domestic institutions 21.94% and the public 6.21%, spread across 61,923 shareholders.

The shareholder count was 61,923 in 2026-Sept, compared with 65,296 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 63.47% 63.48% 66.25% 66.25% 66.25% 66.26% 66.26% 66.26%

Institutional Investors

FII Holding 7.63% 7.68% 8.26% 7.98% 8.53% 8.86% 8.86% 9.26%
DII Holding 21.94% 21.80% 18.37% 18.58% 17.90% 17.50% 17.48% 17.02%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
Public Holding 6.21% 6.27% 6.35% 6.44% 6.53% 6.59% 6.63% 6.67%
Other Holding 0.75% 0.76% 0.77% 0.76% 0.79% 0.79% 0.76% 0.79%
Shareholder Count 61,923 65,296 67,955 65,409 67,785 68,882 70,827 66,896

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Ajanta Pharma. Ajanta Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹28.00 per unit for 2026-March, a yield of 0.85%, compared with ₹28.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹28.00, ₹28.00 and ₹51.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹28.00 0.85%
2025-March ₹28.00 1.00%
2024-March ₹51.00 1.94%
2023-March ₹7.00 0.31%
2022-March ₹9.50 0.79%
2021-March ₹9.50 0.79%
2020-March ₹13.00 1.09%
2019-March ₹9.00 0.99%
2018-March ₹0.00 0.00%
2017-March ₹13.00 1.40%

Ajanta Pharma Stock Index Membership - Nifty & Sensex

See which indices include Ajanta Pharma stock. Check AJANTPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 22 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX LMI250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX LMI250
BSE INDEX MID150
BSE INDEX MIDCAP
BSE INDEX MSL400
NIFTY 500
NIFTY LARGEMID250
NIFTY M150 QLTY50
NIFTY MIDCAP 150
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY PHARMA
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50
NIFTY500 SHARIAH
NIFTYM150MOMNTM50

Ajanta Pharma Market Events Screener - Corporate Actions

Get Ajanta Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Ajanta Pharma stock events that may affect AJANTPHARM share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 30, 2026, with a record date of October 30, 2026.

It is followed by Dividend dated August 5, 2026 and Quarterly Result Announcement dated July 30, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-30 2026-10-30 Quarterly Result Announcement NA 4.87%
2026-08-05 2026-08-05 Dividend ₹ 32.00 /share 3.68%
2026-07-30 2026-07-30 Quarterly Result Announcement NA -0.57%
2026-07-16 2026-07-16 Annual General Meeting NA 10.34%
2026-05-05 2026-05-05 Quarterly Result Announcement NA 4.42%
2026-01-30 2026-01-30 Quarterly Result Announcement NA -2.63%
2025-11-10 2025-11-10 Dividend ₹ 28.00 /share 2.50%
2025-11-03 2025-11-03 Quarterly Result Announcement NA 0.20%
2025-07-28 2025-07-28 Quarterly Result Announcement NA 3.00%
2025-07-17 2025-07-17 Annual General Meeting NA 5.31%
2025-04-30 2025-04-30 Quarterly Result Announcement NA 3.24%
2025-01-30 2025-01-30 Quarterly Result Announcement NA -8.46%
2024-11-06 2024-11-06 Dividend ₹ 28.00 /share 4.74%
2024-10-28 2024-10-28 Quarterly Result Announcement NA -11.03%
2024-07-18 2024-07-18 Annual General Meeting NA -8.03%

Ajanta Pharma Competitors Screener - Peer Stocks Comparison

Screen AJANTPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Ajanta Pharma Company Announcements - News & Reports Screener

Screen AJANTPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 13, 2026.

The next most recent announcements are dated November 4, 2026 and November 2, 2026.

Date Update Actions
2026-11-13 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-11-04 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-02 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-30 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-10-30 Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2026. -
2026-10-30 Board Meeting Outcome for Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2026. -
2026-10-21 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-10-15 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-15 Board Meeting Intimation for Considering And Approving Unaudited Financial Results For Q2 FY 2027 -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-06 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-10-01 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-09-30 Submission Of Sustainability Report For FY 2026 -
2026-09-28 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-09-25 Closure of Trading Window -
2026-09-18 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-08-31 Participation In Investor Conference -
2026-08-31 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-27 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011 -
2026-08-19 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹3,273.80, within a 52-week range of ₹2,485.70 to ₹3,718.20. The P/E ratio is 32.50 and the P/B ratio is 8.45, with earnings per unit of ₹84.53. Market capitalisation stands at ₹41,993.73 Cr and the dividend yield is 0.97%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.